IFNG and non-small cell lung carcinoma: In line with these data, investigators from MedImmune (now AstraZeneca) identified a four-gene IFN-γ+ signature comprising IFN-γ, CD274, LAG3, and CXCL9, which was associated with clinical efficacy of durvalumab in NSCLC and UCC.